Pressmeddelanden från Newbury Pharmaceuticals

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures 12-Month Pazopanib Tender in Denmark 21 jan 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2025 – November 2025 14 jan 11:15

Newbury Pharmaceuticals

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 10 dec 2025 20:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals publishes its annual report for 2024/2025 09 dec 2025 16:15

Newbury Pharmaceuticals

Kallelse till årsstämma i Newbury Pharmaceuticals AB 18 nov 2025 13:50

Newbury Pharmaceuticals

Nordic Market Update 11 nov 2025 13:15

Newbury Pharmaceuticals

Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO 29 okt 2025 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals year-end report September 2024 – August 2025 24 okt 2025 08:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury 23 okt 2025 14:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury 23 sep 2025 08:30

Newbury Pharmaceuticals

Newbury Pharmaceutical, CEO, Lars Minor, will present the company at Økonomisk Ugebrev's Life Science Conference on 24 September 2025 in Copenhagen.11 aug 2025 10:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury 09 jul 2025 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2024 – May 2025 28 apr 2025 09:21

Newbury Pharmaceuticals

Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 16 million and extends the existing SEK 15 million loan agreement 16 apr 2025 13:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury 09 apr 2025 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2024 – February 2025 19 mar 2025 11:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals expands its portfolio with four new products 14 mar 2025 08:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets 24 jan 2025 10:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules 24 jan 2025 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2024 – November 2024 22 jan 2025 09:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets 15 jan 2025 14:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Azelastine + Fluticasone nasal spray 15 jan 2025 11:23

Newbury Pharmaceuticals

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 11 dec 2024 19:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals publishes its annual report for 2023/2024 11 dec 2024 09:30

Newbury Pharmaceuticals

Kallelse till årsstämma i Newbury Pharmaceuticals AB 28 okt 2024 10:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Buspiron 23 okt 2024 11:15

Newbury Pharmaceuticals

Newbury Pharmaceuticals year-end report September 2023 – August 2024 30 sep 2024 09:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals AB has agreed to extend the existing 15 MSEK loan agreement.27 sep 2024 15:56

Newbury Pharmaceuticals

Strong Quarterly Sales Announcement from Newbury Pharmaceuticals 23 sep 2024 13:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden 13 sep 2024 11:30

Newbury Pharmaceuticals

Regulatory Filing for Teduglutide 31 jul 2024 10:04

Newbury Pharmaceuticals

Extraordinary general meeting in Newbury Pharmaceuticals AB (publ)12 jul 2024 09:30

Newbury Pharmaceuticals

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEWBURY PHARMACEUTICALS AB 10 jul 2024 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2023 – May 2024 20 jun 2024 13:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen 18 jun 2024 08:45

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder 10 apr 2024 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2023 – February 2024 04 mar 2024 08:15

Newbury Pharmaceuticals

Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 19 million 22 feb 2024 08:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK 17 jan 2024 10:00

Newbury Pharmaceuticals

Nintedanib Newbury approved by the Swedish Health Authorities 10 jan 2024 11:20

Newbury Pharmaceuticals

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 10 jan 2024 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2023 – November 2023 13 dec 2023 23:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals publishes its annual report for 2022/2023 08 dec 2023 13:00

Newbury Pharmaceuticals

Kallelse till årsstämma i Newbury Pharmaceuticals AB 20 okt 2023 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio with Melatonin Extended Release 2 mg 11 okt 2023 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals year-end report September 2022 – August 2023 06 okt 2023 13:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals has entered into a partnership granting access to 6 registered products.22 sep 2023 10:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide 18 sep 2023 14:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals AB has successfully signed a 15 MSEK loan agreement 23 aug 2023 08:00

Newbury Pharmaceuticals

Newbury gains access to the Nordic hospital market with a new strategic partnership for prescription medicine 19 jul 2023 11:30

Newbury Pharmaceuticals

Desmopressin Newbury approved by the Swedish Health Authorities 16 jun 2023 09:42

Newbury Pharmaceuticals

Newbury Pharmaceuticals sets financial goals for 2024 and 2028 14 jun 2023 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2022 – May 2023 13 jun 2023 17:40

Newbury Pharmaceuticals

Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14 25 maj 2023 13:00

Newbury Pharmaceuticals

Newbury to present at Redeye Growth Day 2023 12 maj 2023 08:30

Newbury Pharmaceuticals

Pirfenidone Newbury approved by the Norwegian Health Authorities 02 maj 2023 11:00

Newbury Pharmaceuticals

Solifenacin/Tamsulosin Newbury approved by the Norwegian Health Authorities 12 apr 2023 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2022 – February 2023 24 mar 2023 11:45

Newbury Pharmaceuticals

Lapatinib Newbury approved by the Swedish Health Authorities 06 mar 2023 14:30

Newbury Pharmaceuticals

Dimethyl Fumarate Newbury approved by the Swedish Health Authorities 02 feb 2023 07:45

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio with Buspirone tablets 11 jan 2023 11:45

Newbury Pharmaceuticals

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 11 jan 2023 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2022 – November 2022 09 jan 2023 08:00

Newbury Pharmaceuticals

International sales orders for 2023 27 dec 2022 10:00

Newbury Pharmaceuticals

Fampridine Newbury approved by the Swedish Health Authorities 14 dec 2022 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals publishes its annual report for 2021/2022 08 dec 2022 12:00

Newbury Pharmaceuticals

Kallelse till årsstämma i Newbury Pharmaceuticals AB 06 dec 2022 07:00

Newbury Pharmaceuticals

Redeye will host two events with Newbury Pharmaceuticals in December 23 nov 2022 09:30

Newbury Pharmaceuticals

Newbury expands its portfolio with two ready to launch products 22 nov 2022 08:00

Newbury Pharmaceuticals

Newbury will participate at the RedEye Life Science Day – 24th November 2022 01 nov 2022 08:30

Newbury Pharmaceuticals

Teriflunomide Newbury approved by the Norwegian Health Authorities 13 okt 2022 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals year-end report September 2021 – August 2022 07 sep 2022 13:15

Newbury Pharmaceuticals

Newbury Pharmaceuticals management has purchased shares in the company 05 sep 2022 15:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals engages Pareto Securities to reduce spread in share price 02 aug 2022 14:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals expands the team with a Head of Business Development 06 jul 2022 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2021 – May 2022 09 jun 2022 07:15

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio with Teriparatide injection in pre-filled pen 26 apr 2022 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio with two new products 13 apr 2022 08:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2021 – February 2022 29 mar 2022 16:30

Newbury Pharmaceuticals

Sunitinib Newbury approved by the Danish Health Authorities 07 mar 2022 08:45

Newbury Pharmaceuticals

Lenalidomide Newbury approved by the Swedish Health Authorities 21 feb 2022 07:15

Newbury Pharmaceuticals

Commercialisation of Icatibant Newbury 15 feb 2022 11:00

Newbury Pharmaceuticals

Newbury on business focus and strategy (Video)11 jan 2022 10:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals AB publishes prospectus regarding offering of newly issued shares prior to listing application on Nasdaq First North Growth Market 21 dec 2021 17:15

Newbury Pharmaceuticals

Newbury Pharmaceuticals interim report September 2021 – November 2021 14 dec 2021 12:45

Newbury Pharmaceuticals

Newbury Pharmaceuticals signs strategic agreement for treatment of short bowel syndrome in the Nordics and strengthens the strategic focus on rare diseases 10 dec 2021 14:00

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its oncology portfolio 21 okt 2021 11:30

Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio and strategic focus